000 | 01899 a2200493 4500 | ||
---|---|---|---|
005 | 20250514052421.0 | ||
264 | 0 | _c20030312 | |
008 | 200303s 0 0 eng d | ||
022 | _a1064-1963 | ||
024 | 7 |
_a10.1081/ceh-120015350 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aAvola, Roberto | |
245 | 0 | 0 |
_aEffect of growth factors on DNA labeling and cytoskeletal protein expression in 17-beta-estradiol and basic fibroblast growth factor pre-treated astrocyte cultures. _h[electronic resource] |
260 |
_bClinical and experimental hypertension (New York, N.Y. : 1993) _c |
||
300 |
_a753-67 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aAnimals, Newborn |
650 | 0 | 4 |
_aAstrocytes _xcytology |
650 | 0 | 4 | _aBlotting, Western |
650 | 0 | 4 |
_aCell Differentiation _xdrug effects |
650 | 0 | 4 |
_aCells, Cultured _xdrug effects |
650 | 0 | 4 |
_aCytoskeletal Proteins _xbiosynthesis |
650 | 0 | 4 |
_aDNA _xbiosynthesis |
650 | 0 | 4 |
_aEpidermal Growth Factor _xtherapeutic use |
650 | 0 | 4 |
_aEstradiol _xtherapeutic use |
650 | 0 | 4 |
_aFibroblast Growth Factor 2 _xtherapeutic use |
650 | 0 | 4 |
_aGrowth Substances _xtherapeutic use |
650 | 0 | 4 |
_aInsulin _xtherapeutic use |
650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xtherapeutic use |
650 | 0 | 4 | _aModels, Animal |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aStaining and Labeling |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aCormaci, Gianfrancesco | |
700 | 1 | _aMazzone, Venera | |
700 | 1 | _aDenaro, Luca | |
700 | 1 | _aMignini, Fiorenzo | |
700 | 1 | _aTomassoni, Daniele | |
700 | 1 | _aZaccheo, Damiano | |
773 | 0 |
_tClinical and experimental hypertension (New York, N.Y. : 1993) _gvol. 24 _gno. 7-8 _gp. 753-67 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1081/ceh-120015350 _zAvailable from publisher's website |
999 |
_c12256545 _d12256545 |